PT  - JOURNAL ARTICLE
AU  - GuoHu, Hong
AU  - Qing, Guan
AU  - Qing, Mao
TI  - Spread dynamics of SARS-CoV-2 epidemic in China: a phylogenetic analysis
AID  - 10.1101/2020.05.20.20107854
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.20.20107854
4099  - http://medrxiv.org/content/early/2020/05/25/2020.05.20.20107854.short
4100  - http://medrxiv.org/content/early/2020/05/25/2020.05.20.20107854.full
AB  - To reveal the detailed spread dynamics of SARS-CoV-2 epidemic in China, a phylogenetic analysis was performed by the Bayesian inference framework tool. 233 strains were retrieved from confirmed cases in China until March 31, 2020. The tMRCA of SARS-CoV-2 strains in China could be traced back to December 9, 2019. According to the effective population size curve reconstructed by Skyline model, this research revealed the influence of travel ban measures on the effective population size in China. Furthermore, we divided the epidemic process of SARS-CoV-2 in China into 4 stages according to the effective population size curve. With the Bayesian stochastic search variable selection method, phylogeographical reconstruction detailedly described the geographic spread behavior of SARS-CoV-2 in each stage and confirmed the importance of travel ban in blocking SARS-CoV-2 cross-regional spread. This article summarizes the influence of prevention and control measures in China, which has a positive impact on the world.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this published article.